Eevia Health Plc's ("Eevia") shares will be listed on Spotlight Stock Market today, June 29, 2021
Eevia Health Plc recently succeeded with an IPO equity round, issuing new 3 451 000 shares with gross proceeds of approx. SEK 26,2 million, leading to a total of 13 951 500 shares in the company as per today's date. Trading in shares will take place from today, June 29, 2021 at Spotlight Stock Market. The short name for the share is EEVIA.
Stein Ulve, CEO: "It is exciting to see Eevia Health listed at Spotlight Stock Market. It is a significant milestone for our Company. Now we may continue focusing on creating growth and value for all constituents of our venture."
See also: Start | Spotlight (spotlightstockmarket.com)
Information about the Eevia Health shares:
Short name: EEVIA
Share name: Eevia Health
FISN: EEVIA HEALTH/SH
Organization number: 2825194-4
Market Segment: SPSE
MIC code: XSAT
Tick table/liquidity band #: 1 (Shares and depositary receipts)
Seinäjoki, Finland June 29, 2021
For more information, please contact:
Stein Ulve, CEO Kim Nurmi-Aro, CFO
Tel.: +358 400 22 5967 +358 504 44 0717
Eevia was founded in 2017 with the mission to address global health problems through the sustainable production and distribution of bioactive plant extracts, which have scientifically documented health benefits. Through utilization of raw material sources, often under-utilized raw materials abundantly available in the Nordic forests, and sometimes inexpensive byproducts from food and woodindustries, Eevia manufactures and markets organically certified nutraceutical ingredients. The products are targeted against immune health, low-grade inflammation, eye and brain health problems and metabolic disorders. The increasing health awareness among consumers, combined with the increased focus on sustainable business models, constitute strong and significant macro-trends. Eevia stands well equipped to capitalize from these trends, resulting in an accelerating growth trajectory.
Eevia is headquartered in Seinäjoki, Finland. As of the end of 2020, the Company had 28 full-time employees and its total revenue for the full year ended December 31st, 2020 was EUR 2.86m. Growth has accelerated in 2021 and extract sales reached EUR 1.9m in the period 1st January - 31st March, corresponding to 560 percent sales growth compared to the same period prior year.
Eevia Health Plc ("Eevia" or "The Company") is welcoming Tuomas Jylhä as interim Chief Financial Officer. Gabriella Beni has decided to leave the Company for personal reasons to focus on private matters. Eevia wishes her the very best in her future endeavors. Tuomas Jylhä will take over the position on July 26th.
Analyst Group Initiates equity research Coverage of Eevia Health Plc, ("Eevia" or "The Company").
Eevia Health Plc receives a 5,8 MSEK/0,55 MEUR sales order for high concentrate anthocyanin organic bilberry extract
Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus.
Eevia Health Plc receives a 230 KSEK/21 KEUR starting sales order for a new Lingonberry product to a new customer
Eevia Health Plc, ("Eevia" or "The Company"), has received a 21 KEUR sales order from its Australian distributor Ingredients Plus for a new product made from Lingonberry, after a new customer has decided to launch a new product with the Lingonberry ingredient as a key component.
Eevia Health Plc has secured a credit line of SEK 8 million for working capital purposes to finance continued growth
Eevia Health Plc, ("Eevia" or "The Company"), has entered into an agreement whereby Exelity AB, Sweden will provide a credit line for Eevia of up to SEK 8 million, giving the Company increased working capital flexibility to finance its continued growth.
The Annual General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the "Company") was held on June 21, 2022 in Seinäjoki, Finland, whereby the shareholders primarily resolved the following matters:
Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.
The shareholders of Eevia Health Abp, company registration number 2825194-4 in Finland, are hereby called for the Annual General Meeting (AGM) to be held on June 21st 2022.
Eevia Health Plc's (''Eevia'' or ''the Company'') Financial Statements for 2021 together with the Auditors' report have been published today.
Eevia Health Plc